Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) has earned an average rating of "Moderate Buy" from the eight analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $18.75.

Several research firms recently weighed in on KLRS. Citigroup reaffirmed an "outperform" rating on shares of Kalaris Therapeutics in a research note on Wednesday, May 13th. Wall Street Zen lowered Kalaris Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, June 14th. Wedbush assumed coverage on Kalaris Therapeutics in a research note on Thursday, May 14th. They set an "outperform" rating and a $17.00 price target for the company. Citizens Jmp decreased their price objective on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 13th. Finally, TD Cowen started coverage on shares of Kalaris Therapeutics in a report on Monday, June 15th. They set a "buy" rating for the company.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in Kalaris Therapeutics in the 2nd quarter valued at approximately $65,000. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics during the third quarter valued at $58,000. Bridgeway Capital Management LLC purchased a new stake in Kalaris Therapeutics during the 3rd quarter worth about $130,000. Woodline Partners LP acquired a new position in Kalaris Therapeutics in the 3rd quarter valued at about $1,394,000. Finally, WHI TRUST Co LLC acquired a new stake in shares of Kalaris Therapeutics during the 4th quarter worth about $823,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

Kalaris Therapeutics Price Performance

Shares of NASDAQ KLRS opened at $4.03 on Monday. The stock has a market capitalization of $95.95 million, a price-to-earnings ratio of -2.00 and a beta of 0.20. Kalaris Therapeutics has a 52 week low of $3.03 and a 52 week high of $11.88. The firm has a 50-day moving average price of $4.17 and a 200 day moving average price of $5.76.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.02. Equities research analysts expect that Kalaris Therapeutics will post -1.99 EPS for the current fiscal year.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source